NCT06555068View on ClinicalTrials.gov

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

528

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Advanced Unresectable or Metastatic Breast Cancer
Interventions
DRUG

HRS-6209 in Combination with Fulvestrant

HRS-6209 in Combination with Fulvestrant

DRUG

HRS-6209 in Combination with HRS-1358

HRS-6209 in Combination with HRS-1358

DRUG

HRS-6209 in Combination with Letrozole

HRS-6209 in Combination with Letrozole

DRUG

HRS-6209 in Combination with HRS-8080

HRS-6209 in Combination with HRS-8080

DRUG

HRS-6209 in Combination with HRS-1358

HRS-6209 in Combination with HRS-1358

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY